<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621542</url>
  </required_header>
  <id_info>
    <org_study_id>D8350004</org_study_id>
    <nct_id>NCT01621542</nct_id>
  </id_info>
  <brief_title>Clinical Study of WT2725 in Patients With Advanced Malignancies</brief_title>
  <official_title>Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity
      of WT2725. WT2725 will be administered to patients with advanced malignancies known to
      overexpress WT1
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with other WT1 vaccines in clinical trials has shown evidence of immunogenicity and
      clinical response in various malignancies.

      This study will assist with determining which dose level(s) to use in future clinical studies
      and will evaluate both clinical and immunological response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2012</start_date>
  <completion_date type="Actual">May 17, 2017</completion_date>
  <primary_completion_date type="Actual">May 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose-limiting Toxicities and Adverse Events</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Evaluation of the safety and tolerability of WT2725 Dosing Emulsion based on the occurrence of DLT and AEs The safety and tolerability of WT2725 Dosing Emulsion will be evaluated based on the occurrence of DLT and AEs, and the findings from clinical laboratory tests, vital signs measurements, body weight measurements, and electrocardiogram (ECG) results. The incidence of DLT will be evaluated during the DLT Evaluation Period, which extends from the day of the first dose to just prior to the fifth dose of study drug (Days 1 to 29). No more than 4 doses of study drug will be administered during the DLT Evaluation Period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of WT2725 Based on the Evaluation of Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Day 1 - Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor Responses to WT2725 Based on the Immune-related Response Criteria (irRC)</measure>
    <time_frame>Day 1 - within 28 days after last dose</time_frame>
    <description>Tumor response, as evaluated according to irRC, was based on total measurable tumor burden in patients with solid tumors (ie, non-AML patients). Tumor assessments will be conducted during screening, and then every 8 weeks after the first dose of study drug. All tumor assessments may be performed within ±7 days of the scheduled assessment. All patients should complete an End of Study visit within 28 days after the last dose of study drug and prior to the start of alternate antineoplastic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response to WT2725</measure>
    <time_frame>Day 1 - within 28 days after last dose</time_frame>
    <description>The modified IWG response criteria were used to assess drug activity in AML patients. Tumor assessments will be conducted during screening, and then every 8 weeks after the first dose of study drug. All tumor assessments may be performed within ±7 days of the scheduled assessment. All patients should complete an End of Study visit within 28 days after the last dose of study drug and prior to the start of alternate antineoplastic therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>WT2725</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WT2725; injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>WT2725</intervention_name>
    <description>WT2725 injection Study drug will be administered every 1-4 weeks</description>
    <arm_group_label>WT2725</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1 Inclusion Criteria:

          -  Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0,
             1, or 2

          -  Patient must have one of the following histologically or cytologically documented
             measurable (may be measureable by tumor markers only, such as quantitative RT-PCR for
             WT1 transcript for AML, or CA-125 for ovarian carcinoma) advanced stage malignancies:
             non-small cell lung, ovarian, glioblastoma, and AML (not including acute promyelocytic
             leukemia), known to overexpress the WT1 protein.

          -  Patient must qualify with a study specific HLA typing assay.

          -  Haematological parameters:

               -  Absolute neutrophil count (ANC) ≥ 1,000/μl

               -  Platelet count ≥ 10.0x10(to the 4th power)/μl (≥ 5.0 x 10(to 4th power)/μl after
                  stem cell transplant)

               -  Hemoglobin ≥ 9.0 g/dL

               -  Absolute lymphocyte count (ALC) ≥ 1,000/μl (≥ 500/μl after stem cell transplant)
                  Note: After completion of dose escalation, patients with AML are not required to
                  meet these hematologic criteria.

          -  Biochemical Parameters:

               -  serum creatinine of ≤ 1.5x upper limit of normal (ULN) for the reference lab.

               -  total bilirubin of ≤ 2.0 mg/dl (≤ 3.0 mg/dl for patients with known Gilbert's
                  syndrome)

               -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the
                  ULN for the reference lab

          -  Patient must have access to archival tumor tissue sample or agree to undergo biopsy
             after study eligibility has been confirmed to obtain fresh sample for evaluation of
             WT1 expression. In place of archival tumor tissue samples, subjects with AML should
             have available a bone marrow aspirate and/or, bone marrow biopsy, with PCR for WT1
             transcript performed before the first dose of study drug.

        Note: The archived tumor tissue sample does not need to be delivered to the clinical site
        prior to enrollment of the patient, however its availability should be confirmed through
        provision of the accession number or other identification number.

        Patient Inclusion Criteria - Part 2:

          -  Patient or his or her legal representatives must give written informed consent and
             privacy authorization prior to participation in the study.

          -  Patient must be willing and able to comply with the study procedures and visit
             schedules and must be able to follow verbal and written instructions.

          -  Patient must be ≥ 18 years of age.

          -  Women of childbearing potential and men with female sexual partners of childbearing
             potential must agree to abstain from sexual intercourse or use a double barrier method
             to determine if a woman is of childbearing potential
             (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).

          -  Patient must have an ECOG Performance Score of 0, 1, or 2 (refer to Appendix II).

          -  Patient has a life expectancy of at least 4 months.

          -  Patient must have histologically or cytologically documented measurable (may be
             measurable by tumor markers only, such as quantitative RT-PCR for WT1 transcript for
             AML) advanced stage glioblastoma or AML (not including acute promyelocytic leukemia),
             known to overexpress the WT1 protein. Note: Determination of WT1 expression will not
             be assessed prior to patient enrollment.

          -  Patient must have an advanced stage malignancy defined as meeting at least one of the
             following criteria:

          -  progressed or recurred despite standard therapy

          -  no standard therapy exists

          -  patient is intolerant of standard therapy

          -  patient is not a candidate for standard therapy

          -  Patient must be HLA-A*0201+ and/or HLA-A*0206+

          -  Patient with glioblastoma must have adequate bone marrow and immune reserve, as
             documented by:

          -  ANC ≥ 1000/μl (≥ 500/μl after stem cell transplant)

          -  Platelet count ≥ 10.0 x 1(to the 4th power)/μl (≥ 5.0 x 10(to the 4th power)/μl after
             stem cell transplant)

          -  Hemoglobin ≥ 9.0 g/dL

          -  ALC ≥ 900/μl (Note: Patients with AML are not required to meet these hematologic
             criteria).

          -  Patient must have adequate renal function documented by a serum creatinine of ≤ 1.5
             times the ULN for the reference lab.

          -  Patient must have adequate hepatic function documented by a total bilirubin of ≤ 2.0
             mg/dl (≤ 3.0 mg/dl for patients with known Gilbert's syndrome) and ALT and AST ≤ 3
             times the ULN for the reference lab.

          -  Patient must have access to archival tumor tissue sample or agree to undergo biopsy
             after study eligibility has been confirmed to obtain fresh sample for evaluation of
             WT1 expression. In place of archival tumor tissue samples, patients with AML should
             have available a bone marrow aspirate and/or bone marrow biopsy with PCR for WT1
             transcript performed before the first dose of study drug.

        Note: The archived tumor tissue sample does not need to be delivered to the clinical site
        prior to enrollment of the patient, however its availability should be confirmed through
        provision of the accession number or other identification number.

        • Patients with AML must be willing to undergo bone marrow aspiration/biopsy during
        treatment if there are no other indicators of measureable disease.

        Part 1 Exclusion Criteria:

          -  Patient with an extensively disseminated primary glioblastoma.

          -  Patient with symptomatic brain metastases, ie, not neurologically stable or requiring
             treatment with corticosteroids, or central nervous system (CNS) leukemia.

          -  Patient with an infection requiring treatment with systemic antibiotics or antiviral
             medication or has completed treatment for such an infection within 4 days prior to
             planned initial dose of WT2725.

          -  Patient requiring systemic, pharmacologic doses of corticosteroids (equivalent to &gt; 60
             mg hydrocortisone/day or 2 mg dexamethasone/day). Replacement doses (equivalent to ≤ 5
             mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as
             needed.

          -  Patient has a positive test for Hepatitis B surface antigen, Hepatitis C antibody,
             human immunodeficiency virus (HIV)-1, or HIV-2 antibody, or has a history of a
             positive result.

          -  Patient has received any of the following treatments within the specified timeframe
             prior to dosing:

               -  endocrine therapy, immunotherapy, transfusion, hematopoietic factors within 14
                  days prior to planned first dose of study drug (Note: After completion of dose
                  escalation, patients with AML are not required to meet these hematologic
                  criteria, eg. transfusions and hematopoietic growth factors.)

               -  chemotherapy including molecular-targeting therapy within 21 days (for
                  molecular-targeted agents that are not associated with myelosuppression or
                  immunosuppression, the minimum interval is 5 half-lives if that is less than 21
                  days)

               -  surgery, radiation, or immunosuppressants within 28 days

               -  investigational drug within 28 days

               -  mitomycin-C or nitrosoureas within 42 days

          -  Patient with an unresolved ≥ Grade 2 AE from a previous antineoplastic treatment,
             excluding alopecia.

          -  Pregnant or lactating women

          -  Patient with an autoimmune condition

          -  Patients with serious unstable medical illness

          -  Patient with pleural effusion, ascites, or pericardial fluid requiring drainage.

          -  Patient is a staff member of the sponsor or clinical site and is involved in the
             conduct of the study or the relative of such a staff member.

        Patient Exclusion Criteria - Part 2:

          -  Patient has an extensively disseminated primary glioblastoma.

          -  Patient has symptomatic brain metastases, ie, presence of neurological symptoms or
             requiring treatment with corticosteroids, or CNS leukemia.

          -  Patient has an infection and has had a body temperature of &gt; 38.3˚C within 48 hours
             prior to planned first dose of study drug.

          -  Patient requires systemic, pharmacologic doses of corticosteroids (equivalent to &gt; 60
             mg hydrocortisone/day or 2 mg dexamethasone/day). Replacement doses (equivalent to ≤ 5
             mg prednisone/day), and topical, ophthalmic, and inhalation steroids are permitted as
             needed.

          -  Patient has a positive test for Hepatitis B surface antigen, Hepatitis C antibody,
             HIV-1, or HIV-2 antibody, or has a history of a positive result.

          -  Patient has received any of the following treatments within the specified timeframe:

               -  endocrine therapy, immunotherapy, transfusion, or hematopoietic factors within 14
                  days prior to planned first dose of study drug (Note: Patients with AML are not
                  required to meet these hematologic criteria, eg, transfusions and hematopoietic
                  growth factors.),

               -  chemotherapy including molecular-targeting therapy within 21 days prior to
                  planned first dose of study drug (for molecular-targeted agents that are notis 5
                  half-lives if that is less than 21 days),

               -  surgery, radiation, or immunosuppressants within 28 days prior to planned first
                  dose of study drug,

               -  investigational drug within the 28 days prior to planned first dose of study
                  drug, or

               -  mitomycin-C or nitrosoureas within 42 days prior to planned first dose of study
                  drug.

        Note: Patients receiving LHRH agonists or antagonists or antiestrogens or aromatase
        inhibitors started and at a stable dose for at least 90 days prior to planned first dose of
        study drug are eligible. Patients are permitted one 28 day cycle of concurrent treatment
        with hydroxyurea during the study.

          -  Patient has an unresolved ≥ Grade 2 AE from a previous antineoplastic treatment,
             excluding alopecia.

          -  Woman who is pregnant or lactating or has a positive pregnancy test at screening. If a
             woman has a positive pregnancy test, further evaluation may be conducted to rule out
             ongoing pregnancy to allow the patient to be eligible.

          -  Patient has an autoimmune condition, including, but not limited to, multiple
             sclerosis, Grave's disease, vasculitis, systemic lupus erythematosus, rheumatoid
             arthritis, systemic sclerosis, myasthenia gravis, ankylosing spondylitis, Wegener's
             granulomatosis, ulcerative colitis, Crohn's disease, psoriasis requiring systemic
             therapy, pemphigus, temporal arteritis, dermatomyositis, Sjögren's syndrome,
             Goodpasture's syndrome, interstitial pneumonitis, interstitial nephritis, or
             Henoch-Schönlein purpura.

          -  Patient has in the opinion of the investigator any intercurrent conditions that could
             preclude their participation in the study, pose an undue medical hazard, or that could
             interfere with the interpretation of the study results, including, but not limited to,
             patients with congestive heart failure (NYHA Class III or IV; refer to Appendix III),
             unstable angina, cardiac arrhythmia requiring treatment, recent (within the prior 6
             months) myocardial infarction, acute coronary syndrome or stroke, severe obstructive
             pulmonary disease, hypertension requiring more than2 medications for adequate control,
             or diabetes mellitus with more than 2 episodes of ketoacidosis in the prior 12 months.

          -  Patient has pleural effusion, ascites, or pericardial fluid requiring drainage. Note:
             Patient who had drain removal ≥ 14 days prior to planned first dose of study drug and
             has no sign of worsening is eligible.

          -  Patient has any other medical, psychiatric, or social condition, including substance
             abuse that in the opinion of the investigator would preclude participation in the
             study.

          -  Patient has had previous treatment with the study drug or other WT1-related vaccine
             therapy.

          -  Patient has a known hypersensitivity to any of the components of the study drug.

          -  Patient is a staff member of the sponsor or clinical site and is involved in the
             conduct of the study or the relative of such a staff member
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vice President Clinical Development and Medical Affairs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center - North Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <results_first_submitted>May 16, 2018</results_first_submitted>
  <results_first_submitted_qc>January 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2019</results_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Oncology</keyword>
  <keyword>Malignancies</keyword>
  <keyword>Wilms' Tumor</keyword>
  <keyword>WT1</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Glioblastoma [GBM]</keyword>
  <keyword>Acute myeloid leukemia [AML]</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Final Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 3, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01621542/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment history</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01621542/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01621542/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>please note that there were two subjects that never received study drug medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>WT2725 0.3 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="P2">
          <title>WT2725 0.9 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="P3">
          <title>WT2725 3.0 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="P4">
          <title>WT2725 9 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="P5">
          <title>WT2725 18 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="P6">
          <title>WT2725 27 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>progression/treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study stopped by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>WT2725 0.3 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="B2">
          <title>WT2725 0.9 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="B3">
          <title>WT2725 3.0 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="B4">
          <title>WT2725 9 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="B5">
          <title>WT2725 18 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="B6">
          <title>WT2725 27 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="8.96"/>
                    <measurement group_id="B2" value="62.6" spread="7.99"/>
                    <measurement group_id="B3" value="63.0" spread="9.25"/>
                    <measurement group_id="B4" value="57.5" spread="15.46"/>
                    <measurement group_id="B5" value="51.3" spread="16.14"/>
                    <measurement group_id="B6" value="59.4" spread="15.83"/>
                    <measurement group_id="B7" value="58.0" spread="14.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status [n(%)] The Eastern Cooperative Oncology Group (ECOG) score</title>
          <description>Grade Performance Status 0 Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work
Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours
Capable of only limited self care, confined to bed or chair more than 50% of waking hours
Completely disabled. Cannot carry on any self care. Totally confined to bed or chair
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Dose-limiting Toxicities and Adverse Events</title>
        <description>Evaluation of the safety and tolerability of WT2725 Dosing Emulsion based on the occurrence of DLT and AEs The safety and tolerability of WT2725 Dosing Emulsion will be evaluated based on the occurrence of DLT and AEs, and the findings from clinical laboratory tests, vital signs measurements, body weight measurements, and electrocardiogram (ECG) results. The incidence of DLT will be evaluated during the DLT Evaluation Period, which extends from the day of the first dose to just prior to the fifth dose of study drug (Days 1 to 29). No more than 4 doses of study drug will be administered during the DLT Evaluation Period.</description>
        <time_frame>Up to 4 months</time_frame>
        <population>Safety Population (defined as all enrolled patients who received at least one dose of study drug.)</population>
        <group_list>
          <group group_id="O1">
            <title>WT2725 0.3 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O2">
            <title>WT2725 0.9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O3">
            <title>WT2725 3.0 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O4">
            <title>WT2725 9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O5">
            <title>WT2725 18 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O6">
            <title>WT2725 27 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Dose-limiting Toxicities and Adverse Events</title>
          <description>Evaluation of the safety and tolerability of WT2725 Dosing Emulsion based on the occurrence of DLT and AEs The safety and tolerability of WT2725 Dosing Emulsion will be evaluated based on the occurrence of DLT and AEs, and the findings from clinical laboratory tests, vital signs measurements, body weight measurements, and electrocardiogram (ECG) results. The incidence of DLT will be evaluated during the DLT Evaluation Period, which extends from the day of the first dose to just prior to the fifth dose of study drug (Days 1 to 29). No more than 4 doses of study drug will be administered during the DLT Evaluation Period.</description>
          <population>Safety Population (defined as all enrolled patients who received at least one dose of study drug.)</population>
          <units>number of occurances</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of WT2725 Based on the Evaluation of Dose-limiting Toxicity (DLT)</title>
        <time_frame>Day 1 - Day 29</time_frame>
        <population>Safety Population (defined as all enrolled patients who received at least one dose of study drug.)</population>
        <group_list>
          <group group_id="O1">
            <title>WT2725 0.3 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O2">
            <title>WT2725 0.9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O3">
            <title>WT2725 3.0 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O4">
            <title>WT2725 9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O5">
            <title>WT2725 18 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O6">
            <title>WT2725 27 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of WT2725 Based on the Evaluation of Dose-limiting Toxicity (DLT)</title>
          <population>Safety Population (defined as all enrolled patients who received at least one dose of study drug.)</population>
          <units>Dose Limiting Toxicity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The MTD could not be established for this study as no DLTs occurred at doses up to and including 27.0 mg</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>None specified</non_inferiority_desc>
            <other_analysis_desc>The MTD could not be established for this study as no DLTs occurred at doses up to and including 27.0 mg</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antitumor Responses to WT2725 Based on the Immune-related Response Criteria (irRC)</title>
        <description>Tumor response, as evaluated according to irRC, was based on total measurable tumor burden in patients with solid tumors (ie, non-AML patients). Tumor assessments will be conducted during screening, and then every 8 weeks after the first dose of study drug. All tumor assessments may be performed within ±7 days of the scheduled assessment. All patients should complete an End of Study visit within 28 days after the last dose of study drug and prior to the start of alternate antineoplastic therapy.</description>
        <time_frame>Day 1 - within 28 days after last dose</time_frame>
        <population>Efficacy irRC population: including all the patients in the Safety population who are not AML patients and whose lesions are measureable and have at least one posttreatment assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>WT2725 0.3 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O2">
            <title>WT2725 0.9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O3">
            <title>WT2725 3.0 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O4">
            <title>WT2725 9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O5">
            <title>WT2725 18 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O6">
            <title>WT2725 27 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Antitumor Responses to WT2725 Based on the Immune-related Response Criteria (irRC)</title>
          <description>Tumor response, as evaluated according to irRC, was based on total measurable tumor burden in patients with solid tumors (ie, non-AML patients). Tumor assessments will be conducted during screening, and then every 8 weeks after the first dose of study drug. All tumor assessments may be performed within ±7 days of the scheduled assessment. All patients should complete an End of Study visit within 28 days after the last dose of study drug and prior to the start of alternate antineoplastic therapy.</description>
          <population>Efficacy irRC population: including all the patients in the Safety population who are not AML patients and whose lesions are measureable and have at least one posttreatment assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response to WT2725</title>
        <description>The modified IWG response criteria were used to assess drug activity in AML patients. Tumor assessments will be conducted during screening, and then every 8 weeks after the first dose of study drug. All tumor assessments may be performed within ±7 days of the scheduled assessment. All patients should complete an End of Study visit within 28 days after the last dose of study drug and prior to the start of alternate antineoplastic therapy.</description>
        <time_frame>Day 1 - within 28 days after last dose</time_frame>
        <population>Efficacy population for modified IWG response: includes all the AML patients in the Safety population who have &gt;5% marrow blasts or &gt;50 copy/μｇRNA of quantitative RT-PCR for WT1 transcript before the first date/time of study drug and who have at least one posttreatment assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>WT2725 0.3 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O2">
            <title>WT2725 0.9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O3">
            <title>WT2725 3.0 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O4">
            <title>WT2725 9 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O5">
            <title>WT2725 18 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
          <group group_id="O6">
            <title>WT2725 27 mg</title>
            <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response to WT2725</title>
          <description>The modified IWG response criteria were used to assess drug activity in AML patients. Tumor assessments will be conducted during screening, and then every 8 weeks after the first dose of study drug. All tumor assessments may be performed within ±7 days of the scheduled assessment. All patients should complete an End of Study visit within 28 days after the last dose of study drug and prior to the start of alternate antineoplastic therapy.</description>
          <population>Efficacy population for modified IWG response: includes all the AML patients in the Safety population who have &gt;5% marrow blasts or &gt;50 copy/μｇRNA of quantitative RT-PCR for WT1 transcript before the first date/time of study drug and who have at least one posttreatment assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One month</time_frame>
      <desc>Serious adverse events (SAEs) will be defined as: • AEs that occurred on or after the first dose of study drug and on or before the 30th day after the last dose of study drug, • AEs with a missing start date and a stop date on or after the first dose of study drug, or • AEs with both a missing start and stop date.</desc>
      <group_list>
        <group group_id="E1">
          <title>WT2725 0.3 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="E2">
          <title>WT2725 0.9 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="E3">
          <title>WT2725 3.0 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="E4">
          <title>WT2725 9 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="E5">
          <title>WT2725 18 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
        <group group_id="E6">
          <title>WT2725 27 mg</title>
          <description>WT2725; injection WT2725: WT2725 injection Study drug will be administered every 1-4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>WT2725 Medical Director</name_or_title>
      <organization>Sunovion Pharmaceuticals Inc.</organization>
      <phone>1-866-503-6351</phone>
      <email>clinicaltrialsdisclosure@sunovion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

